Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
10.1371/journal.pmed.1003773
10.1371/journal.pmed.1003773 · External reference
10.1038/s41591-021-01283-z
10.1038/s41591-021-01283-z · External reference
10.1101/2021.03.03.21252086
10.1101/2021.03.03.21252086 · External reference
10.1136/bmjgh-2021-005427
10.1136/bmjgh-2021-005427 · External reference
10.1101/2022.07.28.22278159
10.1101/2022.07.28.22278159 · External reference
Summary of joint guideline on the management of long COVID
10.1002/psb.1941 · 2021 · External reference
10.1101/2021.11.17.21263608
10.1101/2021.11.17.21263608 · External reference
10.1101/2022.01.05.22268800
10.1101/2022.01.05.22268800 · External reference
Covid-19: one in eight adults develops long covid symptoms, study suggests
10.1136/bmj.o1946 · 2022 · External reference
10.1016/j.molmed.2021.06.002
10.1016/j.molmed.2021.06.002 · External reference
Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome
10.1073/pnas.2024358118 · 2021 · External reference
Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: a possible approach to SARS-CoV-2 ‘long-haulers’?
2020 · External reference
Persistent SARS-2 infections contribute to long COVID-19
10.1016/j.mehy.2021.110538 · 2021 · External reference
10.1101/2022.06.14.22276401
10.1101/2022.06.14.22276401 · External reference
10.1042/bcj20220016
10.1042/bcj20220016 · External reference
10.21203/rs.3.rs-1139035/v1
10.21203/rs.3.rs-1139035/v1 · External reference
10.1016/j.ijid.2021.10.045
10.1016/j.ijid.2021.10.045 · External reference
Prevalence and persistent shedding of fecal SARS-CoV-2 RNA in patients with COVID-19 infection: a systematic review and meta-analysis
10.14309/ctg.0000000000000343 · 2021 · External reference
Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues
10.1073/pnas.2105968118 · 2021 · External reference
10.1093/infdis/jiab490
10.1093/infdis/jiab490 · External reference
Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning
10.3389/fimmu.2021.700782 · 2021 · External reference
10.1016/j.cell.2022.01.014
10.1016/j.cell.2022.01.014 · External reference
10.1016/j.immuni.2022.01.017
10.1016/j.immuni.2022.01.017 · External reference
Immunomodulatory effects of fluoxetine: a new potential pharmacological action for a classic antidepressant drug?
10.1016/j.phrs.2015.11.021 · 2016 · External reference
Selective serotonin reuptake inhibitors as a novel class of immunosuppressants
10.1016/j.intimp.2014.02.030 · 2014 · External reference
The influence of antidepressants on the immune system
10.1007/s00005-019-00543-8 · 2019 · External reference
Study on anti-inflammatory and immunomodulatory effects of fluoxetine in rat models of inflammation
10.1177/1721727x15618671 · 2015 · External reference
10.1016/j.euroneuro.2007.03.010
10.1016/j.euroneuro.2007.03.010 · External reference
The immunomodulatory effect of the antidepressant sertraline in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis
10.1159/000321634 · 2011 · External reference
10.1182/blood-2012-06-437392
10.1182/blood-2012-06-437392 · External reference
Serotonin reduction in post-acute sequelae of viral infection
2023 · External reference
10.1007/s00406-020-01231-x
10.1007/s00406-020-01231-x · External reference
Psychotropic drugs: therapeutic perspectives against Covid-19
2021 · External reference
10.1126/scitranslmed.aau5266
10.1126/scitranslmed.aau5266 · External reference
Overview of the potential use of fluvoxamine for COVID-19 and long COVID
10.1007/s44192-023-00036-3 · 2023 · External reference
Interactions of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells
10.1016/j.ejphar.2014.01.064 · 2014 · External reference
Inflammation and clinical response to treatment in depression: a meta-analysis
10.1016/j.euroneuro.2015.06.007 · 2015 · External reference
The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis
10.1038/npp.2011.132 · 2011 · External reference
Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment
10.1055/s-0029-1202263 · 2009 · External reference
The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery
10.1016/j.psyneuen.2014.03.019 · 2014 · External reference
Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial
10.1007/s00213-013-3322-3 · 2014 · External reference
Identifying who has long COVID in the USA: a machine learning approach using N3C data
10.1016/s2589-7500(22)00048-6 · 2022 · External reference
Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs
10.1111/joim.12197 · 2014 · External reference
10.1016/s2214-109x(21)00448-4
10.1016/s2214-109x(21)00448-4 · External reference
Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study
10.1038/s41380-021-01021-4 · 2021 · External reference
Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants
10.1001/jamanetworkopen.2021.33090 · 2021 · External reference
Antidepressant use and risk of intubation or death in hospitalized patients with COVID-19: a retrospective cohort study of clinical effectiveness
10.3389/fpsyt.2022.951065 · 2022 · External reference
Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial
10.1001/jama.2020.22760 · 2020 · External reference
10.1056/nejmoa2201662
10.1056/nejmoa2201662 · External reference
10.1093/ofid/ofac492.1881
10.1093/ofid/ofac492.1881 · External reference
10.1101/2023.09.12.23295424
10.1101/2023.09.12.23295424 · External reference
10.1007/s00228-022-03372-5
10.1007/s00228-022-03372-5 · External reference
Antidepressant drug prescription and incidence of COVID-19 in mental health outpatients: a retrospective cohort study
2023 · External reference
10.1016/j.cmi.2023.04.028
10.1016/j.cmi.2023.04.028 · External reference
Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: a population-based study
10.1016/j.euroneuro.2023.03.011 · 2023 · External reference
10.3390/microorganisms11082073
10.3390/microorganisms11082073 · External reference
Treatment of 95 post-covid patients with ssris
2023 · External reference
